TY - JOUR
T1 - Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1
AU - Pastorino, L
AU - Andreotti, V
AU - Dalmasso, B
AU - Vanni, I
AU - Ciccarese, G
AU - Mandalà, M
AU - Spadola, G
AU - MA, Pizzichetta
AU - Ponti, G
AU - MG, Tibiletti
AU - Sala, E
AU - Genuardi, Maurizio
AU - Chiurazzi, Pietro
AU - Maccanti, G
AU - Manoukian, S
AU - Sestini, S
AU - Danesi, R
AU - Zampiga, V
AU - La, Starza R
AU - Stanganelli, I
AU - Ballestrero, A
AU - Mastracci, L
AU - Grillo, F
AU - Sciallero, S
AU - Cecchi, F
AU - ET, Tanda
AU - Spagnolo, F
AU - Queirolo, P
AU - (IMI), Italian Melanoma Intergroup
AU - AM, Goldstein
AU - Bruno, W
AU - Ghiorzo, P.
PY - 2020
Y1 - 2020
N2 - The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet to be determined. Multigene panel testing could increase diagnostic yield and better define the role of candidate genes. We characterized 273 CDKN2A/ARF and CDK4-negative probands through a custom-designed targeted gene panel that included CDKN2A/ARF, CDK4, ACD, BAP1, MITF, POT1, TERF2IP, ATM, and PALB2. Co-segregation, loss of heterozygosity (LOH)/protein expression analysis, and splicing characterization were performed to improve variant classification. We identified 16 (5.9%) pathogenic and likely pathogenic variants in established high/medium penetrance cutaneous melanoma susceptibility genes (BAP1, POT1, ACD, MITF, and TERF2IP), including two novel variants in BAP1 and 4 in POT1. We also found four deleterious and five likely deleterious variants in ATM (3.3%). Thus, including potentially deleterious variants in ATM increased the diagnostic yield to about 9%. Inclusion of rare variants of uncertain significance would increase the overall detection yield to 14%. At least 10% of melanoma missing heritability may be explained through panel testing in our population. To our knowledge, this is the highest frequency of putative ATM deleterious variants reported in melanoma families, suggesting a possible role in melanoma susceptibility, which needs further investigation.
AB - The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet to be determined. Multigene panel testing could increase diagnostic yield and better define the role of candidate genes. We characterized 273 CDKN2A/ARF and CDK4-negative probands through a custom-designed targeted gene panel that included CDKN2A/ARF, CDK4, ACD, BAP1, MITF, POT1, TERF2IP, ATM, and PALB2. Co-segregation, loss of heterozygosity (LOH)/protein expression analysis, and splicing characterization were performed to improve variant classification. We identified 16 (5.9%) pathogenic and likely pathogenic variants in established high/medium penetrance cutaneous melanoma susceptibility genes (BAP1, POT1, ACD, MITF, and TERF2IP), including two novel variants in BAP1 and 4 in POT1. We also found four deleterious and five likely deleterious variants in ATM (3.3%). Thus, including potentially deleterious variants in ATM increased the diagnostic yield to about 9%. Inclusion of rare variants of uncertain significance would increase the overall detection yield to 14%. At least 10% of melanoma missing heritability may be explained through panel testing in our population. To our knowledge, this is the highest frequency of putative ATM deleterious variants reported in melanoma families, suggesting a possible role in melanoma susceptibility, which needs further investigation.
KW - melanoma
KW - melanoma
UR - https://publicatt.unicatt.it/handle/10807/167893
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85083959471&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85083959471&origin=inward
U2 - 10.3390/cancers12041007
DO - 10.3390/cancers12041007
M3 - Article
SN - 2072-6694
SP - 1
EP - 17
JO - Cancers
JF - Cancers
IS - 4
ER -